GH Research (GHRS) Share-based Compensation (2021 - 2026)
GH Research (GHRS) posted quarterly Share-based Compensation of $2.7 million for Q4 2025, up 249.93% year-over-year from $759000.0 in Q4 2024, and up 15.48% quarter-over-quarter from $2.3 million in Q3 2025.
GH Research (GHRS) Share-based Compensation (2021 - 2026) Analysis & Trends
GH Research's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.7 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 249.93% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $8.5 million (up 586.97% YoY), while the FY2025 annual figure was $13.1 million, up 167.72% from the prior year.
- Share-based Compensation for Q4 2025 stood at $2.7 million, up from $2.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $2.7 million in Q4 2025, with the low at -$100000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $444000.0 (2022), against an average of $768444.4.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 125.0% in 2024, then jumped 2000.0% in 2025.
- GH Research's Share-based Compensation stood at $269000.0 in 2021, then jumped by 81.41% to $488000.0 in 2022, then surged by 33.4% to $651000.0 in 2023, then grew by 16.59% to $759000.0 in 2024, then soared by 249.93% to $2.7 million in 2025.
- Business Quant data shows GHRS's Share-based Compensation at $2.7 million in Q4 2025, $2.3 million in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Jun 30, 2026 | 2.20 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 759,000.00 |
| Dec 31, 2024 | 759,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 651,000.00 |
| Dec 31, 2023 | 651,000.00 |